Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up on Analyst Upgrade

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $46.00 to $58.00. The stock had previously closed at $44.18, but opened at $46.59. Guggenheim currently has a buy rating on the stock. Maze Therapeutics shares last traded at $45.24, with a volume of 35,021 shares traded.

Other analysts also recently issued reports about the stock. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Wedbush boosted their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Wells Fargo & Company assumed coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. BTIG Research lifted their target price on Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Raymond James Financial started coverage on Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $48.57.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.02, for a total value of $690,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction on Thursday, January 29th. The shares were sold at an average price of $44.27, for a total value of $332,025.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $464,967.81. This represents a 41.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 200,000 shares of company stock valued at $8,254,792 in the last ninety days.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the fourth quarter valued at approximately $145,000. Invesco Ltd. lifted its holdings in Maze Therapeutics by 1.5% during the fourth quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock worth $5,553,000 after buying an additional 1,971 shares during the period. ADAR1 Capital Management LLC boosted its position in Maze Therapeutics by 589.3% during the 4th quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after acquiring an additional 153,487 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of Maze Therapeutics by 22.9% in the 4th quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock valued at $1,368,000 after acquiring an additional 6,154 shares during the period. Finally, Wellington Management Group LLP bought a new position in shares of Maze Therapeutics in the 4th quarter worth $2,536,000.

Maze Therapeutics Stock Performance

The business has a 50 day moving average of $43.79 and a two-hundred day moving average of $34.04. The stock has a market capitalization of $2.24 billion, a PE ratio of -2.22 and a beta of 4.47.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.